Nebenwirkungen · Shingrix
Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted) · Abschnitt 4.8 · PDF-Seite 6
HOS-137978 · Präparat HOS-098121
In 2 similar post-marketing observational studies in the US among individuals aged 65 years or older, an increased risk of Guillain-Barré syndrome (estimated 3 to 7 excess cases per million doses administered) was observed during the 42 days following any dose of Shingrix. In further analyses, the increased risk was observed following the first dose of Shingrix (estimated 6 to 12 excess cases of Guillain-Barré syndrome per million doses administered), but no increased risk was observed following the second dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T02:00:00Z · SHA-256 85082087d1e78d824692b73311f74bd22f2c91f3bb63e85a50437dd6319c83bc · Passage b04d5f81fa17ae9de4bdfdcbfaf8b15fa7da508d112c4c1382a8c2f34cfda171 · Zeichen 4118–4635 im Abschnitt